Medicinal Mushrooms in the Integrative Care of Gastrointestinal Cancer
Yoon Hang Kim MD | www.directintegrativecare.com
Membership-Based Telemedicine | Integrative & Functional Medicine
Medicinal Mushrooms in the Integrative Care of Gastrointestinal Cancer
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Introduction
Gastrointestinal (GI) malignancies — including esophageal, gastric, hepatocellular, biliary tract, pancreatic, and colorectal cancers — collectively account for roughly one in four cancer diagnoses worldwide and a disproportionate share of cancer mortality. Standard cytotoxic and targeted therapies have improved outcomes, yet patients continue to contend with significant treatment-related toxicity, immunosuppression, fatigue, and reduced quality of life. In this context, integrative oncology has matured from a marginal discipline to a recognized adjunct, and medicinal mushrooms occupy a particularly evidence-informed place within that toolkit.
Medicinal mushrooms have been used in East Asian medical traditions for more than two thousand years. Modern oncology adopted them more formally in the 1970s and 1980s, when polysaccharide-K (PSK, krestin) from Trametes versicolor and lentinan from Lentinula edodes were approved in Japan as adjuncts to conventional cancer therapy. Since then, the literature has expanded to include reishi (Ganoderma lucidum), maitake (Grifola frondosa), Agaricus blazei, Cordyceps species, lion's mane (Hericium erinaceus), and the shiitake-derived AHCC preparation. This article reviews the mechanistic rationale and the clinical evidence for medicinal mushrooms in GI cancer, with particular attention to turkey tail and reishi.
At Direct Integrative Care, we view medicinal mushrooms not as alternatives to chemotherapy, radiation, or immunotherapy, but as evidence-informed supportive agents that may improve tolerability, preserve immune competence, and — in selected populations — extend disease-free survival when integrated alongside standard care.
Mechanistic Foundations: Why Mushrooms?
The bioactivity of medicinal mushrooms in oncology derives primarily from three classes of compounds: high-molecular-weight β-glucans and protein-bound polysaccharides, triterpenoids, and a smaller contribution from peptides and nucleoside derivatives. β-(1→3)/(1→6)-glucans are recognized by pattern-recognition receptors on innate immune cells — most importantly Dectin-1, complement receptor 3 (CR3), and Toll-like receptors 2 and 4 — which initiates a cascade involving macrophage activation, dendritic cell maturation, NK-cell cytotoxicity, and Th1-polarized adaptive immunity [1,2].
Triterpenoids, abundant in reishi, exert distinct effects: inhibition of NF-κB and downstream inflammatory cytokines, induction of apoptosis through both intrinsic (mitochondrial) and extrinsic pathways, and modulation of the tumor microenvironment [3]. A growing body of preclinical work also demonstrates that selected mushroom extracts modulate chemoresistance pathways — most notably through downregulation of heat shock factor 1 and HSP27 (a known mediator of gemcitabine resistance), inhibition of JAK2/STAT3, and modulation of P-glycoprotein-mediated drug efflux [4].
These mechanisms are clinically relevant in GI oncology. Cytotoxic chemotherapy frequently produces lymphopenia, neutropenia, and mucosal injury — precisely the parameters where polysaccharide-rich extracts have demonstrated benefit. Where immune checkpoint inhibitors (e.g., the addition of durvalumab in biliary tract cancer) are part of the regimen, the Th1 and NK-cell biases of mushroom polysaccharides are mechanistically aligned with, rather than opposed to, the goals of treatment.
Turkey Tail (Trametes versicolor)
The strongest evidence base in GI oncology
Turkey tail is the most extensively studied medicinal mushroom in oncology. PSK (krestin), a protein-bound β-glucan extract derived from the CM-101 strain of T. versicolor, was approved as an adjunctive cancer therapy in Japan in 1977 and became, for several decades, one of the best-selling anticancer drugs in that country. PSP (polysaccharide-peptide) is a structurally related extract with comparable immunomodulatory activity [5].
The clinical evidence in GI cancer is substantial. A 2006 individual-patient-data meta-analysis of three randomized controlled trials including 1,094 patients with curatively resected colorectal cancer demonstrated that adjuvant PSK (3 g/day) added to standard chemotherapy was associated with a statistically significant improvement in overall survival and disease-free survival, with a 9% absolute reduction in 5-year mortality and a number-needed-to-treat of approximately 11 [6]. A 2007 individual-patient-data meta-analysis in resected gastric cancer (eight trials, 8,009 patients) similarly demonstrated improved overall and disease-free survival with adjuvant PSK [7].
A 2017 network meta-analysis of 23 randomized controlled trials encompassing 10,684 patients with gastrointestinal cancers concluded that PSK plus chemotherapy was superior to chemotherapy alone for overall survival across one to seven years of follow-up, with the strongest signals in colorectal and gastric cancer [8]. A 2019 systematic review and meta-analysis pooling C. versicolor and G. lucidum trials likewise reported a significant survival advantage in gastric cancer (HR 0.74; 95% CI 0.62–0.87) [9].
A 2022 Cochrane review of Coriolus versicolor in colorectal cancer adopted a more cautious tone, judging the certainty of evidence as low to very low for individual outcomes such as neutropenia, oral mucositis, nausea, and fatigue, while acknowledging signals of benefit and an excellent safety profile [10]. The discrepancy between the older Japanese trials and the Cochrane synthesis reflects differences in trial methodology, era, and adjudication standards rather than a refutation of clinical effect; the directionality remains favorable.
Practical considerations
- Standardized PSK dose in clinical trials: 3 g/day, typically initiated postoperatively and continued through adjuvant chemotherapy.
- PSP (polysaccharide-peptide) is the closely related extract used in much of the Hong Kong and Chinese literature; doses range from 1 to 3 g/day.
- Hot-water extracts standardized to β-glucan content are preferred over raw mycelium powders, which may contain primarily indigestible starch.
- Adverse events are uncommon and predominantly mild gastrointestinal — darkening of stool, mild loose stools, occasional nausea.
- Drug-interaction concerns are minimal; PSK has been combined with virtually every conventional chemotherapy backbone in Japanese practice for over four decades.
Reishi (Ganoderma lucidum)
The premier triterpenoid mushroom
Reishi (Ling Zhi in Chinese, Reishi in Japanese) occupies a different niche than turkey tail. Where turkey tail is fundamentally a polysaccharide medicine, reishi delivers a more complex pharmacologic profile combining β-glucans with a uniquely rich triterpenoid fraction (ganoderic acids, lucidenic acids, and related compounds). This dual composition produces both immunomodulatory and direct apoptotic effects on tumor cells in vitro, and confers the hepatoprotective signal that makes reishi particularly interesting in hepatobiliary and pancreatic disease [3,11].
The Cochrane review of reishi in cancer treatment (2016) analyzed five randomized controlled trials and concluded that G. lucidum could be administered as an adjunct to conventional cancer therapy, citing potential to enhance tumor response, stimulate host immunity, and improve quality of life, with a favorable safety profile and rare minor adverse events [12]. The review did not find sufficient evidence to support reishi as a first-line cancer treatment — a position with which most integrative oncologists agree.
A 2023 narrative review focused specifically on reishi in gastrointestinal malignancies summarized preclinical and clinical evidence across colorectal, gastric, hepatocellular, and pancreatic cancer, identifying consistent signals for inhibition of proliferation, induction of apoptosis, suppression of metastasis, and modulation of autophagy through PI3K/AKT/mTOR, Wnt/β-catenin, and NF-κB pathways [13]. Ganoderic acid A has demonstrated radiosensitizing effects in human hepatoma models, and reishi polysaccharides have been shown to mitigate cancer-related cachexia in animal studies [13].
Patient-reported outcomes are where reishi has its most consistent clinical signal. A randomized controlled trial of Ganopoly (reishi polysaccharide extract) in patients with advanced cancer demonstrated improvements in fatigue, sleep quality, and general well-being, alongside increases in NK-cell activity and CD3+/CD4+/CD8+ T-cell populations [12].
Practical considerations
- Triterpenoid-standardized extracts (look for products listing percent triterpenes, typically 4–8%) are preferred when the goal includes hepatoprotection or direct cytostatic activity.
- Polysaccharide-standardized extracts (typically 12–40% β-glucans) are preferred when the primary goal is immunomodulation.
- Typical clinical doses range from 1.5 to 3 g/day of standardized extract, divided.
- Reishi exhibits mild antiplatelet activity in vitro; caution is advised in patients on anticoagulation or with thrombocytopenia, although clinically significant bleeding is rare in published trials.
- Cytochrome P450 effects are modest; theoretical interactions with CYP2E1 and CYP3A4 substrates have been described but are unlikely to be clinically meaningful at standard doses.
Other Medicinal Mushrooms with GI-Cancer Relevance
Shiitake (Lentinula edodes) and AHCC
Lentinan, a purified β-(1→3)-glucan from shiitake, has been used as an injectable adjunct to chemotherapy in advanced gastric cancer in Japan since 1985. Multiple clinical trials and retrospective analyses suggest improvements in survival, quality of life, and chemotherapy tolerability when lentinan is combined with fluoropyrimidine-based regimens [14]. Oral shiitake extracts do not reproduce the parenteral lentinan pharmacology and should not be considered equivalent.
AHCC (Active Hexose Correlated Compound) is a fermented mycelial extract derived primarily from shiitake. Its evidence base in GI cancer is particularly relevant. In animal models, AHCC has demonstrated synergy with gemcitabine through downregulation of HSP27 — a mechanism directly germane to pancreatic and biliary tract cancer chemoresistance [4,15]. In a randomized clinical trial of 75 patients with pancreatic adenocarcinoma receiving gemcitabine-based chemotherapy, the addition of AHCC 6 g/day for two months produced a significant reduction in grade 3 adverse events (17% vs 53%, P=0.0005) and in chemotherapy-induced taste disorders (17% vs 56%, P=0.0007) [16]. Earlier work also documented reduced hematologic toxicity in pancreatic and biliary cancer patients on gemcitabine [17].
AHCC has demonstrated improved postoperative outcomes in hepatocellular carcinoma in a prospective cohort study, with reductions in recurrence rate and improvements in overall survival [18]. Two clinically meaningful caveats: AHCC induces CYP2D6 and aromatase in preclinical models, which may theoretically reduce the efficacy of substrates including doxorubicin, ondansetron, tamoxifen, and aromatase inhibitors; clinical significance remains unestablished [19].
Maitake (Grifola frondosa)
Maitake D-fraction is a standardized β-glucan extract with a particular emphasis on hematologic support and innate immune activation. A phase II study in 21 patients with myelodysplastic syndromes demonstrated that maitake extract 3 mg/kg twice daily for 12 weeks produced significant increases in neutrophil and monocyte function with favorable tolerability [20]. In GI cancer specifically, maitake is most often used as a supportive adjunct for patients with chemotherapy-induced cytopenias rather than as a direct antitumor agent.
Agaricus blazei Murill
Agaricus blazei has been studied principally in gynecologic cancer, where a randomized trial demonstrated improved NK-cell activity and quality of life in patients on chemotherapy [21]. Extrapolation to GI malignancy is reasonable but rests on weaker direct evidence. Notably, hepatotoxicity has been reported with certain Agaricus preparations, and caution is warranted in hepatocellular and biliary disease [22].
Cordyceps (Cordyceps militaris and C. sinensis)
Cordyceps is most often deployed in integrative oncology for fatigue, exercise tolerance, and renal-protective effects during cisplatin-based chemotherapy. Cordycepin (3'-deoxyadenosine) has demonstrated proapoptotic and antiproliferative effects in multiple GI cancer cell lines, including hepatocellular and colorectal models, but high-quality clinical trials in GI malignancy are limited [2].
Lion's Mane (Hericium erinaceus)
Lion's mane has demonstrated antitumor and antimetastatic activity in colorectal cancer animal models, with reports of reduced lung metastases in murine experiments [1]. Its more compelling near-term clinical role in oncology, however, is in mitigating chemotherapy-induced peripheral neuropathy and chemotherapy-related cognitive impairment (“chemo-brain”) through its neurotrophic effects, mediated by hericenones and erinacines that stimulate nerve growth factor production.
Clinical Integration in GI Cancer
Evidence-informed integration of medicinal mushrooms into the care of a GI cancer patient requires three considerations: alignment with the chemotherapy backbone, attention to organ-specific physiology, and rigorous product quality control.
For patients on fluoropyrimidine- or oxaliplatin-based regimens (colorectal, gastric), turkey tail PSK at 3 g/day has the strongest evidence base. For patients on gemcitabine-based regimens (pancreatic, biliary), AHCC 3 to 6 g/day has the most directly relevant clinical and mechanistic data, particularly given its HSP27 effects. For hepatocellular carcinoma, both AHCC and reishi have favorable signals, with reishi's triterpenoid fraction offering additional hepatoprotection. For patients on combination regimens that include checkpoint inhibitors (e.g., gemcitabine/cisplatin/durvalumab in biliary tract cancer), turkey tail and reishi remain mechanistically aligned with the immunologic goals of treatment.
Quality control is non-trivial. Many over-the-counter products labeled as “turkey tail” or “reishi” contain primarily mycelium grown on grain substrate, with the final product dominated by indigestible α-glucan starch rather than the bioactive β-glucans of the fruiting body or hot-water extract. Patients and physicians should look for products that disclose β-glucan content (rather than total polysaccharide), specify hot-water or dual-extraction preparation, and provide third-party testing for heavy metals and contaminants. For AHCC specifically, only the original Amino Up preparation matches the formulation studied in the published clinical trials.
Safety, Drug Interactions, and Contraindications
Medicinal mushrooms used at standard clinical doses have an excellent safety profile across decades of use. Adverse effects are typically mild and gastrointestinal — soft stools, mild nausea, and occasional pruritus. Serious adverse events are rare but have been reported, including hepatotoxicity with certain Agaricus preparations and idiosyncratic cytopenias [22].
Drug-interaction considerations relevant to GI oncology include AHCC-mediated CYP2D6 and aromatase induction (potentially reducing the activity of doxorubicin, ondansetron, tamoxifen, and aromatase inhibitors), modest theoretical antiplatelet effects with reishi, and the general principle that any high-dose botanical merits a conversation with the treating oncologist before initiation [19]. Patients with active biliary obstruction, severe hepatic dysfunction, or on transplant immunosuppression require individualized assessment before starting any medicinal mushroom protocol.
Conclusion
Medicinal mushrooms — particularly turkey tail, reishi, AHCC, and lentinan — represent one of the most evidence-informed categories of integrative agents in gastrointestinal oncology. The strongest data support adjunctive use for tolerability, immune preservation, and, in selected colorectal and gastric populations, modest improvements in disease-free and overall survival. They are not curative agents and should not be presented as such. They are, however, well-tolerated, mechanistically rational, and supported by a clinical literature spanning four decades.
At Direct Integrative Care, we work with patients and their oncology teams to integrate these therapies thoughtfully — matching the right mushroom to the right chemotherapy backbone, the right organ system, and the right quality-controlled product. Integrative oncology is not an alternative to standard care. Done well, it makes standard care more tolerable and, sometimes, more effective.
References
1. Panda SK, Sahoo G, Swain SS, Luyten W. Anticancer activities of mushrooms: a neglected source for drug discovery. Pharmaceuticals (Basel). 2022;15(2):176.
2. Blagodatski A, Yatsunskaya M, Mikhailova V, Tiasto V, Kagansky A, Katanaev VL. Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. Oncotarget. 2018;9(49):29259-29274.
3. Ahmad R, Riaz M, Khan A, et al. Ganoderma lucidum (Reishi) an edible mushroom: a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. Phytother Res. 2021;35(11):6030-6062.
4. Suenaga S, Kuramitsu Y, Kaino S, et al. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Anticancer Res. 2014;34(1):141-146.
5. Habtemariam S. Trametes versicolor (Synn. Coriolus versicolor) polysaccharides in cancer therapy: targets and efficacy. Biomedicines. 2020;8(5):135.
6. Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006;55(4):404-411. PMID: 16133112.
7. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905-911. PMID: 17106715.
8. Sun Y, Hu B, Sun WB, Pang DJ, Wang B, Zhou ML. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? A systematic review and network meta-analysis. Oncotarget. 2017;8(51):89108-89118.
9. Zhong L, Yan P, Lam WC, Yao L, Bian Z. Coriolus versicolor and Ganoderma lucidum related natural products as an adjunct therapy for cancers: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2019;10:703.
10. Roberts H, Greenwood R, Donovan EE, Jones C, Hilliam R, Brown M, et al. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database Syst Rev. 2022;11(11):CD012053. PMID: 36445793.
11. Sohretoglu D, Huang S. Ganoderma lucidum polysaccharides as an anti-cancer agent. Anticancer Agents Med Chem. 2018;18(5):667-674. PMID: 27685898.
12. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;4(4):CD007731. PMID: 27045603.
13. Ren A, Wang H, Zhu Z, Ye Y. A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer. Chin Med. 2023;18(1):107.
14. Zhang M, Zhang Y, Zhang L, Tian Q. Mushroom polysaccharide lentinan for treating different types of cancers: a review of 12 years clinical studies in China. Prog Mol Biol Transl Sci. 2019;163:297-328.
15. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222(2):152-158. PMID: 17555784.
16. Yanagimoto H, Satoi S, Yamamoto T, et al. Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutr Cancer. 2016;68(2):234-240.
17. Ito T, Urushima H, Sakaue M, et al. Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy: the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr Cancer. 2014;66(3):377-382.
18. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37(1):78-86.
19. Memorial Sloan Kettering Cancer Center. About Herbs: AHCC. Updated 2024. Available at: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ahcc.
20. Wesa KM, Cunningham-Rundles S, Klimek VM, et al. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother. 2015;64(2):237-247.
21. Ahn WS, Kim DJ, Chae GT, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004;14(4):589-594.
22. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol. 2006;36(12):808-810.
About Dr. Kim
Dr. Yoon Hang “John” Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed the Fellowship in Integrative Medicine at the University of Arizona under Dr. Andrew Weil and is board-certified in Preventive Medicine, with additional certifications in Medical Acupuncture (UCLA) and Integrative & Holistic Medicine. He specializes in low-dose naltrexone (LDN), autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of three books and more than twenty professional articles.
Pr ofessional: www.yoonhangkim.com | Clinical:www.directintegrativecare.com
